Compared with placebo, the time to first moderate or severe exacerbation was longer with mepolizumab. HealthDay News — For patients with chronic obstructive pulmonary disease (COPD) with a ...

For patients with chronic obstructive pulmonary disease (COPD) with a history of ... Compared with placebo, the time to first moderate or severe exacerbation was longer with mepolizumab (419 ...

Former smokers with COPD reporting higher perceived stress had poorer scores on respiratory health assessments, according to ...

MONDAY, May 12, 2025 (HealthDay News) -- For patients with chronic obstructive pulmonary disease (COPD) with a history ... the time to first moderate or severe exacerbation was longer with ...

AstraZeneca presented data from the phase 3 BATURA study which showed that use of Airsupra in those with mild asthma reduced ...

Mepolizumab significantly reduced the annualized rate of moderate or severe ... among patients with COPD who had been admitted to the hospital with a severe exacerbation and a blood eosinophil ...

Initiated Phase 2 Seabreeze STAT Asthma and Seabreeze STAT COPD studies evaluating rademikibart as an adjunct treatment for acute exacerbations in Asthma and COPD in May 2025; topline data expected in ...

In a phase 3, double-blind, randomized, placebo-controlled trial, patients with COPD, a history of ... to control for multiplicity, were moderate or severe exacerbation as assessed in a time ...

AstraZeneca to showcase latest research on comprehensive portfolio and pipeline aimed at transforming respiratory diseases at ATS 2025: Cambridge, UK Wednesday, May 14, 2025, 13:0 ...

Poster P275: Ensifentrine Monotherapy Improved Lung Function and Reduced Exacerbation Rate and Risk in Symptomatic Patients With Moderate-to-Severe COPD ...

In the study, Nucala was added to inhaled maintenance therapy for COPD. The antibody also showed a 31% reduction in the annualised rate of moderate/severe ... due to an exacerbation that could ...